
    
      Participants are to receive 500 mg/mÂ² of capecitabine orally (PO) twice daily (BID) on days 1
      to 14. Courses repeat every 21 days in the absence of disease progression or unacceptable
      toxicity. After completion of study treatment, patients are followed up for 2 years.
    
  